News Articles

On March 7, 2023 BVT announced positive second year trial results demonstrating the efficacy of BVT’s proprietary biological control agent Clonostachys rosea strain CR-7 (CR-7) as a seed treatment on …

Read More

On March 6, 2023 BVT announced that it has closed a non-brokered private placement of 1,491,667 units (the “Units”) issued at a price of $0.12 per Unit for gross aggregate …

Read More

On February 22, 2023 BVT announced Rutgers University has successfully completed year 2 research trials on the efficacy of BVT’s proprietary Vectorite with CR-7 (Clonostachys rosea CR-7), applied with bee …

Read More

On January 31, 2023 BVT released a letter to shareholders from Chief Executive Officer Ashish Malik announcing the financial results for the fourth quarter and fiscal year ended September 30, …

Read More